Name: 為什麼人人都在討論「猛健樂」？糖尿病藥變身減肥神器解析！(What is MOUNJARO? How it works and how this Diabetes Drug Became a Weight Loss Game-Changer!)
Uploaded: 2025-11-06T21:01:30.000Z
Duration: 10 min 13 s

Mounjaro, the new kid on the block that everyone's talking about,

猛健樂，這個大家都在討論的新玩意兒，

and maybe the next big thing in weight loss and diabetes treatment.

可能是減重和糖尿病治療的下一個重量級藥物。

Well, Mounjaro is the brand name for tirzepatide, a drug that takes what Ozempic and Wegovy do, but levels it up.

嗯，猛健樂是 tirzepatide 的品牌名稱，這是一種藥物，它做了胰妥讚（Ozempic）和週纖達（Wegovy）的事情，但把它提升了一個檔次。

It's the first medication to target not just one, but two different gut hormones.

它是第一種不僅針對一種，而是兩種不同腸道荷爾蒙的藥物。

Now, this is part of a series where I explain the drugs you're taking or thinking about taking,

現在，這是我的系列影片之一，我會解釋你們正在服用或考慮服用的藥物，

because let's be honest, half the time when we pop pills, we don't really know what's going on inside us.

因為說實話，很多時候我們吃藥丸，都不知道身體裡到底發生了什麼。

So I'll cover why we need it, how it works, and what the side effects are,

所以我會講到我們為什麼需要它、它是如何作用的，以及有哪些副作用，

and then be sure to stick around, because the science behind this one is actually pretty wild.

然後請務必繼續收看，因為這個藥物的科學原理其實相當驚人。

We're talking dual hormone action, huge weight loss results, and big pharma racing to cash in.

我們在談論雙重荷爾蒙作用、巨大的減重效果，以及大型製藥公司競相獲利。

This drug is pretty similar to Ozempic, which tends to hog the headlines.

這款藥物和胰妥讚非常相似，其總是佔據新聞頭條。

And if you want to find out about that one and Wegovy, you can watch that video up there.

如果你想了解那款藥物和週纖達，可以收看上面的影片。

But here, with this kind of weight loss, it should be called Kilimanjaro, because your appetite disappears into thin air.

不過在這裡，這種減重效果，應該叫做吉力馬札羅山，因為你的食慾就這樣消失得無影無蹤。

You know what, there's probably a better joke there, but whatever, let's go.

說真的，也許有更好的笑話，但不管了，我們繼續。

那麼，你為什麼需要猛健樂呢？

Well, officially, it's a treatment for Type 2 diabetes.

嗯，官方來說，它是治療第二型糖尿病的藥物。

It helps regulate blood sugar, improves insulin sensitivity,

它有助於調節血糖、改善胰島素敏感度，

and keeps those glucose spikes under control.

Clinical trials showed that Mounjaro users lost an average of 20% of their body weight,

臨床試驗顯示，猛健樂的使用者平均減掉了 20% 的體重，

which is even more than we saw with Ozempic and Wegovy.

這比我們在胰妥讚和週纖達上看到的還要多。

Because it doesn't just work on one hormone like semaglutide does.

因為它不像 semaglutide 那樣只作用於一種荷爾蒙。

Now, at the time of this video, it's technically only FDA approved for diabetes right now.

嗯，在我們錄製這支影片的當下，它技術上來說只獲得美國食品藥物管理局核准用於糖尿病。

But that hasn't stopped people from getting it off label for weight loss.

但這並沒有阻止大家為了減重而仿單外使用。

And in 2023, Eli Lilly, the company that makes it,

而在 2023 年，禮來公司，也就是製造它的公司，

got approval for a weight loss version called Zepbound,

也獲得了名為 Zepbound 的減重版本核准，

which is literally the same, just under a different name.

它跟猛健樂基本上是完全一樣的，只是名字不同。

Exactly the same drug, exactly the same doses, but, you know, different Scrabble points.

完全一樣的藥物，完全一樣的劑量，但你知道的，就像是拼字遊戲的分數不同。

So whether you're on Manjaro for diabetes or Zepbound for weight loss,

所以，無論你是為了糖尿病使用猛健樂，還是為了減重使用 Zepbound，

you're getting the same dual-action magic.

你都獲得了相同的雙重荷爾蒙作用魔力。

All right, so this is where it gets interesting.

好的，接下來就變得很有趣了。

Ozempic and Wegovy work by mimicking a hormone called GLP-1,

胰妥讚和週纖達的作用方式是模仿一種叫做 GLP-1 的荷爾蒙，

which helps regulate blood sugar, slows digestion, and suppresses appetite.

它有助於調節血糖、減緩消化，以及抑制食慾。

If you want me to go into detail about that, then just watch that video up there.

如果你想讓我詳細說明的話。那就去看上面那個影片。

猛健樂不只做到這些，還能做得更多。

It targets GLP-1 and GIP, which is glucose dependent insulinotropic peptide.

它針對 GLP-1 和 GIP，也就是葡萄糖依賴性促胰島素多肽。

Well, it helps the body release insulin, just like GLP-1.

嗯，它能幫助身體釋放胰島素，就像 GLP-1 一樣。

It reduces glucagon, meaning less sugar gets dumped into your blood.

它會降低升糖素，表示你的血液中釋放的糖分會減少。

GIP receptors are also found in fat cells,

meaning that this drug might be changing how your body stores and burns fat.

這表示這種藥物可能會改變你身體儲存和燃燒脂肪的方式。

So by hitting both GLP-1 and GIP, Mounjara doesn't just suppress appetite.

所以透過同時作用於 GLP-1 和 GIP，猛健樂不僅能抑制食慾。

It might actually boost your metabolism in ways that semaglutide-based drugs can't.

它實際上可能會以 semaglutide 為基礎的藥物無法做到的方式來提升你的新陳代謝。

And that's why the weight loss results are even bigger.

這也是為什麼減重效果會更顯著。

It's like Ozempic, but with a second turbo boost.

它就像胰妥讚，但有第二個渦輪增壓。

好的，所以猛健樂聽起來很棒，對吧？

So just like Ozempic, Mounjaro slows digestion,

所以就像胰妥讚一樣，猛健樂會減緩消化，

which means nausea, vomiting, diarrhea, constipation.

這意味著噁心、嘔吐、腹瀉、便祕。

Basically, if there's a way for your gut to be upset, this drug will find it.

基本上，如果你的腸道有任何不舒服的方式，這種藥物都會找到。

People on these drugs have a higher risk of gallstones.

服用這些藥物的人罹患膽結石、胰臟炎的風險較高。

Pancreatitis, like other GLP-1 drugs, there's a rare but serious risk of pancreas inflammation, which is not nice.

就像其他的 GLP-1 藥物一樣，有極低但嚴重的胰臟發炎風險，這可不好受。

And muscle loss, because the weight loss is so rapid that you could lose muscle as well as fat.

還有肌肉流失，因為體重下降的速度太快，你可能會同時流失肌肉和脂肪。

You might also get Ozempic face from rapid weight loss of fat up here,

你也可能因為這裡脂肪快速流失而出現「臭氧臉」，

which ends up being more of a psychological rather than a physical issue.

這最終會變成心理問題而非生理問題。

And, well, thyroid cancer, again, that's just like with Ozempic.

然後，嗯，甲狀腺癌，這點跟胰妥讚一樣。

There is a theoretical risk based on rat studies, but there's no clear evidence in humans yet.

這是基於老鼠研究的理論風險，但目前還沒有明確的人類證據。

But if there is a family history of medullary thyroid cancer, which is a rare one,

但如果你有髓質甲狀腺癌的家族史，這是一種罕見的癌症，

or if you have multiple endocrine neoplasia syndrome 2, which is called MEN2,

或者你有第二型多發性內分泌腫瘤症候群，也稱為 MEN 2，

And that brings us to risk versus reward.

這就帶我們來談談風險與報酬。

For people with Type 2 diabetes or obesity, Mounjaro might be a game changer.

對於第二型糖尿病或肥胖症患者來說，猛健樂可能是個劃時代的選擇。

But for someone just looking to shed a few vanity pounds, the side effects might not be worth it.

但如果只是想減掉幾磅愛美用的體重，副作用可能就不值得了。

It could actually UNO reverse your vanity card into something much worse.

這反而可能讓你的愛美卡變成更糟的東西。

And if you're wondering, is this right for me?

Well, ask a doctor, not just the comments section on Instagram.

那就去問醫生，別只看 Instagram 的留言區。

Unlike Ozempic, which was adapted from lizard spit.

和胰妥讚不同，胰妥讚是從蜥蜴的唾液改良而來的。

Mounjaro was designed from the ground up by Eli Lilly to be a dual receptor agonist.

猛健樂是由禮來公司從頭設計，作為一個雙重受體促效劑。

The journey of tirzepatide begins with a focus on enhancing treatments for Type 2 diabetes.

tirzepatide 的旅程始於專注於改善第二型糖尿病的治療。

Recognizing the success of GLP-1 receptor agonists like semaglutide,

鑑於 semaglutide 等 GLP-1 受體促效劑的成功，

researchers aimed to create a more comprehensive solution by targeting multiple pathways involved in glucose regulation and appetite control.

研究人員旨在透過鎖定參與葡萄糖調節和食慾控制的多重途徑，創造一個更全面的解決方案。

This dual agonism was intended to improve blood sugar control and promote weight loss more effectively than existing therapies.

這個雙重促效作用旨在比現有的療法更有效地改善血糖控制並促進體重減輕。

The SURPASS Phase 3 program commenced in late 2018.

SURPASS 第三期計畫於 2018 年底開始。

Encompassing five global registration trials and two regional trials in Japan.

包含五項全球註冊試驗和兩項日本地區試驗。

These studies, ranging from 40 to 52 weeks,

evaluated the efficacy and the safety of tirzepatide as both a monotherapy and an add-on to traditional diabetes treatments.

評估了 tirzepatide 作為單一療法以及合併傳統糖尿病治療的療效和安全性。

Following the success in diabetes management, the Summount Phase 3 program began in late 2019,

在糖尿病管理取得成功後，Summount 第三期計畫於 2019 年底開始。

This program enrolled over 5,000 participants with obesity across multiple studies.

這項計畫在多項研究中招募了超過 5,000 名肥胖症參與者。

The primary period of Surmount 1 concluded in 2022,

Surmount 1 的主要期間於 2022 年結束，

demonstrating significant weight loss in participants without diabetes.

顯示在沒有糖尿病的參與者身上體重顯著減輕。

And so in May 2022, the FDA approved tirzepatide under the brand name Mounjaro for improving glycemic control in adults with Type 2 diabetes.

所以，在 2022 年 5 月，美國食品藥物管理局準許了 tirzepatide 以猛健樂的品牌名稱用於改善第二型糖尿病成人患者的血糖控制。

And building on its weight loss efficacy, Eli Lilly then pursued approval for obesity treatment as well.

為鞏固其減重功效，禮來公司隨後也尋求用於肥胖症治療的準許。

And in November 2023, the FDA approved tirzepatide under the brand name Zeppbound for chronic weight management in overweight or obese adults

接著在 2023 年 11 月，美國食品藥物管理局準許了 tirzepatide 以 Zepbound 的品牌名稱，用於治療體重過重或肥胖

with at least one weight-related health condition like diabetes or heart problems.

且至少有一項與體重相關的健康問題（例如糖尿病或心臟病）的成人，用於慢性體重管理。

I mean we have an overweight and obesity problem, don't we?

我的意思是，我們有體重過重和肥胖的問題，對吧？

And that's cultural, it's societal, but it's also vanity.

這既是文化問題，也是社會問題，但也是愛美的問題。

And that's two things way beyond the scope of this video.

這兩點都遠遠超出了這支影片的討論範圍。

But just like there'll always be a market in babies and there'll always be a market in old people and death,

但就像總會有嬰兒市場、總會有老人和死亡市場一樣，總會有一個市場，

there will always be a market in what people in the boardroom call for fat people.

是那些在董事會裡的人稱之為「胖子市場」的。

And there's probably a bigger market in people who think they're fat but aren't really.

而那些認為自己胖但實際上並非如此的人，市場可能更大。